Aceragen, Inc.: Nasdaq/NYSE listing notice — Idera Pharmaceuticals receives Nasdaq delisting notice over bid price non-compliance

Aceragen, Inc.

Notified by Nasdaq Staff of delisting due to continued non-compliance with minimum $1.00 bid price.
Company plans to timely request a hearing before Nasdaq Hearings Panel to stay delisting.
Previous grace periods expired on November 21, 2022; no further automatic compliance period.
Panel may grant extension up to 180 days, through May 22, 2023, at its discretion.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Aceragen, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

November 22, 2022, Idera Pharmaceuticals, Inc. (the “Company”) was notified by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that, based upon the Company’s continued non-compliance with Nasdaq Listing Rule 5550(a)(2), which requires maintenance of a minimum closing bid price of $1.00 per share (the “Bid Price Requirement”), the Company’s securities were subject to delisting unless the Company timely requested a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company plans to timely request a hearing before the Panel, which request wil

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001104659-22-121727

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.